Yet across this complexity, one structural issue persists:
What works locally rarely scales globally.
While teams continuously innovate, high performing initiatives often remain trapped within markets, functions, or local repositories. The result?
- Duplicate campaigns
- Recreated assets
- Lost time searching for existing initiatives
- Limited visibility on execution excellence
- Transformation programs struggling to show measurable ROI
In 2025, three global leaders - Haleon, Merck and Organon — took a different approach.
They decided to scale what works.
The Shift: From Knowledge Storage to Execution Performance
Traditional intranets and repositories were not the issue. Content existed.
What was missing was:
- Structured validation of best practices
- Incentives to share and reuse
- Measurable visibility on cross-market impact
- A scalable execution model
That’s where Wegrow came in — not as another content tool, but as a global best-practice engine designed to transform local excellence into reusable global assets.
Haleon: Unlocking Global Marketing Execution Capacity
Operating across 160+ markets, Haleon needed a structured way to capture and scale high-performing Marketing and Commercial initiatives.
The result:
- 203 days unlocked across 1,400 users
- €160K+ in measured productivity gains
- Cross-market reuse validating a scalable global execution model
Beyond productivity, the key shift was cultural:
Leadership endorsement and structured recognition reinforced sharing and reuse — turning best practices into a strategic asset rather than static documentation.
Merck: Turning Reuse into Scalable Value Creation
Within Medical and Commercial teams, access to best practices previously required hours — sometimes days — of searching across multiple platforms.
By centralizing validated initiatives:
- 203 days unlocked across 700 users
- €160K+ in measured productivity gains
- 73 proven cross-market reuses
Those 73 reuses are critical. They represent initiatives that were not recreated locally. They reflect avoided duplication, faster execution, and a scalable model capable of unlocking significantly higher value at full rollout.
For global Pharma organizations, reuse is not an engagement metric.
It is an efficiency and growth lever.
Organon: Proving Value Early in Transformation
For Organon, the objective was different: launch a global ESS and Customer Engagement initiative with rapid adoption and measurable results.
Within months:
- 306 days unlocked across 1,700 users
- €80K+ in measured productivity gains
- Strong cross-market engagement validating transformation momentum
The impact was not just operational.
It demonstrated that change initiatives can generate visible value early — a key factor in sustaining executive support.
Why This Matters Now
Pharma and Healthcare organizations are under increasing pressure to:
- Optimize cost structures
- Accelerate launches
- Improve cross-market consistency
- Deliver measurable ROI from transformation initiatives
The inability to scale what works has a direct business cost.
When teams recreate initiatives that already exist elsewhere in the organization, capacity is lost.
When validated practices are hard to find, execution slows.
When transformation lacks measurable outcomes, momentum fades.
Scaling best practices is not a “knowledge management” initiative.
It is an execution strategy.
From Early Gains to Scalable Upside
Across Haleon, Merck, and Organon, early results demonstrate:
- Hundreds of validated best practices structured and reusable
- Measurable days unlocked across global teams
- Documented cross-market reuse
- Tangible productivity gains
Importantly, these gains represent early, observable impact — not the ceiling.
At scale, reuse-driven execution models unlock significantly larger upside through:
- Faster rollout of proven initiatives
- Reduced duplication across markets
- Better allocation of high-value team capacity
- Increased growth potential from accelerated deployment of what works
The Strategic Question for Pharma Leaders
If 200+ days can be unlocked in early deployment phases, what becomes possible at full global scale?
If proven initiatives can be reused rather than recreated, how much capacity can be redirected toward launches, HCP engagement, and innovation?
If transformation initiatives can demonstrate measurable value within months, how does that change executive confidence?
From Fragmented Excellence to Scalable Impact
The lesson from Haleon, Merck, and Organon is clear:
Local excellence is not enough.
Global organizations need mechanisms to:
- Capture what works
- Validate it
- Scale it
- Measure it
Because in today’s Pharma and Healthcare landscape,
execution speed and reuse are competitive advantages.
